Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 grams
Price: Negotiable
Packaging Details: 1kg/Bag; 25kg/Carton
Delivery Time: 2-3 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Purity: |
≥99% |
Molecular Formula: |
C13H19N3O7 |
Density: |
1.46 G/cm3 |
Cas Number: |
2349386-89-4 |
Flash Point: |
316.5°C |
Storage: |
Store At -20°C |
Refractive Index: |
1.617 |
Appearance: |
White To Off-white Powder |
Origin: |
China |
Package: |
1kg/bag, 25kg/drum |
Purity: |
≥99% |
Molecular Formula: |
C13H19N3O7 |
Density: |
1.46 G/cm3 |
Cas Number: |
2349386-89-4 |
Flash Point: |
316.5°C |
Storage: |
Store At -20°C |
Refractive Index: |
1.617 |
Appearance: |
White To Off-white Powder |
Origin: |
China |
Package: |
1kg/bag, 25kg/drum |
Molnupiravir is an antiviral drug that has gained attention for its potential to treat viral infections, particularly in the context of the COVID-19 pandemic. Molnupiravir has shown broad-spectrum antiviral activity against various RNA viruses, including coronaviruses. Since FIP is caused by a coronavirus, there is a theoretical basis for investigating whether Molnupiravir could inhibit the replication of the virus responsible for FIP.
There are several factors to consider when exploring the use of Molnupiravir for FIP treatment. These include the severity of the disease, the stage at which the cat is diagnosed, potential side effects, and the cost-effectiveness of treatment. Additionally, FIP can manifest in various forms, including wet (effusive) and dry (non-effusive) forms, which may influence treatment strategies.
| Solubility: | Soluble In DMSO And Methanol |
| Flash Point: | 316.5°C |
| Boiling Point: | ~600.3°C At 760 MmHg |
| Density: | 1.46 G/cm3 |
| Appearance: | White To Off-white Powder |
| Storage: | Store At -20°C |
| Purity: | ≥99% |
| Refractive Index: | 1.617 |
| Synonyms: | EIDD-2801; MK-4482; Molnupiravir Prodrug |
| Cas Number: | 2349386-89-4 |
1. COVID-19 Treatment: Molnupiravir has been studied extensively as a potential treatment for COVID-19, caused by the SARS-CoV-2 virus. Clinical trials have evaluated its efficacy and safety in patients with mild to moderate COVID-19 symptoms. Results from some studies suggest that Molnupiravir may reduce the duration of symptoms and decrease the risk of hospitalization when administered early in the course of the disease.
2. Antiviral Therapy: Molnupiravir's mechanism of action involves inhibiting the replication of RNA viruses by introducing errors into their genetic material. This broad-spectrum antiviral activity makes it a candidate for treating various viral infections beyond COVID-19, including influenza, respiratory syncytial virus (RSV), and others. Research is ongoing to explore its effectiveness against different viral pathogens.
3. Preventive Treatment: There is interest in exploring Molnupiravir as a preventive treatment for viral infections, particularly in high-risk populations or during outbreaks. If proven effective, it could be used prophylactically to reduce the spread of viral diseases.
4. Animal Health: Molnupiravir may also find applications in veterinary medicine for treating viral infections in animals. This could include diseases affecting livestock, companion animals, and other species vulnerable to viral pathogens.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
